CA-PATIENT-SAFETY
10.11.2021 14:02:09 CET | Business Wire | Press release
Medical errors claim the lives of nearly three million individuals across the globe every year. In any other high-risk industry, like aviation and nuclear power, these numbers would not be acceptable. Yet, the healthcare industry has continued to allow these events to occur—putting patients and staff at risk. The Patient Safety Movement Foundation (PSMF) , a global non-profit committed to achieving zero preventable patient harm and death across the globe by 2030, believes that to reach this goal healthcare organizations that provide care to patients need to commit to operating as highly reliable organizations (HROs) to reduce preventable medical harm. To support this, PSMF launched its new HRO Champion Program and is excited to recognize the first seven healthcare organizations that have committed to this effort. These HRO Champions include: Kaiser Permanente Northern California, Parrish Medical Center (Titusville, Fla.), Hospital Puebla (Puebla, Mexico), Hospitales Star Medica (Mexico City, Mexico), Hospital Materno Infantil Irapuato (Irapuato, Mexico), Hospital de Especialidades Pediatrico Leon (San Jose del Potrero, Mexico) and Hospital Español (Granada, Mexico).
“The pandemic exposed gaps in the global healthcare system, which forced us to examine the processes in place and identify ways we can prioritize patient safety,” stated Dr. Mike Ramsay, CEO of PSMF. “We are proud to recognize and unite healthcare systems that share this mission and provide them resources to help improve their processes and eliminate preventable harm in their organizations.”
The new HRO Champions program puts an emphasis on data transparency, as this is a critical component to achieving zero harm and improving patient safety. To participate, hospitals and healthcare organizations commit to sharing their adverse event and near-miss data, once annually, to measure the impact of improvements in the network over time. Not only does transparency hold health systems accountable, but it also makes it easier for patients to access safety information to make informed healthcare decisions.
“We are honored to have been designated as HRO Champions by the Patient Safety Movement Foundation, in which we have found a valuable ally to continue improving our care processes,” stated Jose Testas Anton, vice president of Hospital Español. “At Hospital Español, we believe that being able to share and collaborate with other health systems and provide information related to patient safety outside the walls of our organization will help generate collaborative learning and promote patient safety around the world.”
“We are pleased to be recognized for our unwavering commitment to provide safe and reliable patient care and commend our staff for being strong advocates for and partnering with their patients to prevent unnecessary harm,” said Robin Betts, vice president of safety, quality and regulatory services for Kaiser Permanente Northern California. “Our hospitals are among the country’s highest performing for minimizing patient injuries, medication errors and infections. We have processes in place, which closely align with the Patient Safety Movement Foundation to highlight potential safety issues for our care teams who focus every day on protecting the health of their patients, keeping them safe from harm and providing the highest quality care.”
By committing to zero harm, healthcare organizations are eligible for many different benefits, including free coaching, workshops, publicity and other tools. HRO Champions are announced every month and can submit data any time throughout the year to be eligible. Learn more about how to become a HRO Champion: https://patientsafetymovement.org/take-action/organizational-action/going-above-and-beyond/hro-champions/
About the Patient Safety Movement Foundation: Each year, more than 200,000 people die in U.S. hospitals and more than three million globally as a result of unsafe care. The Patient Safety Movement Foundation (PSMF) is a global non-profit with a vision to eliminate preventable patient harm and death across the globe by 2030. PSMF unites patients, advocates, healthcare providers, medical technology companies, government, employers and private payers in support of this cause. From its Actionable Patient Safety Solutions and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero. For more information, please visit patientsafetymovement.org , and follow PSMF on LinkedIn , Twitter , Instagram and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005553/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 10:00:00 CET | Press release
The two partners launch “Bianca”, the first large-scale digitalisation initiative in Italy focused on histopathological samples, aimed at training AI algorithms to support pathologists’ diagnostic activities. The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying
OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 10:00:00 CET | Press release
OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with
New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 10:00:00 CET | Press release
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro
Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 10:00:00 CET | Press release
Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 09:15:00 CET | Press release
This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment OptionsOveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency that Causes Narcolepsy Type 1The Prescription Drug User Fee Act (PDUFA) Target Action Date is the Third Quarter of this Calendar Year Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
